<DOC>
	<DOC>NCT01733992</DOC>
	<brief_summary>The purpose of this study is to determine the safety, tolerability and pharmacokinetics of R348 eye drops in patients with dry eye disease.</brief_summary>
	<brief_title>A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease</brief_title>
	<detailed_description>This is a randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate the ocular tolerability, safety, and pharmacokinetics of R348 administered in patients with mild to moderate keratoconjunctivitis sicca (KCS).</detailed_description>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Mild to moderate Keratoconjunctivitis Sicca. A corrected visual acuity in both eyes of 20/40 or better. An intraocular pressure of &lt; 21 mm Hg with a difference between eyes of &lt; 6 mm Hg. History or evidence of ocular infection, inflammation, or conjunctivitis within 2 months prior to the first dosing day. History or evidence of blepharitis requiring the use of antibiotics or eye scrubs within 2 months prior to the first dosing day. History of herpes simplex keratitis at any time. Current ocular allergy symptoms. Recent use of eye medications such as steroids or cyclosporine Refractive eye surgery within 12 months of the first dosing day. Other eye surgeries within 4 months of the first dosing day. Current use of contact lenses or discontinuation of contact lens use within 2 weeks of the first dosing day. Receipt of any blood or blood products within 90 days prior to the first dosing day. Participation in any clinical study within 30 days prior to the first dosing day. History of disease, or currently have a significant illness or abnormal laboratory finding as determined by your study doctor. Positive for hepatitis B, hepatitis C or HIV. Smoked regularly within 12 months of first dosing day. History of substance abuse, drug addiction or alcoholism.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>